Join Growin Stock Community!

Aclaris therapeutics, inc.ACRS.US Overview

US StockHealthcare
(No presentation for ACRS)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ACRS AI Insights

ACRS Overall Performance

ACRS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ACRS Recent Performance

0.52%

Aclaris therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

ACRS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ACRS Key Information

ACRS Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ACRS Profile

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Price of ACRS

ACRS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ACRS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.60
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
19.75
PB Ratio
2.59
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
6.93%
Net Margin
-829.58%
Revenue Growth (YoY)
-58.20%
Profit Growth (YoY)
-83.39%
3-Year Revenue Growth
-44.93%
3-Year Profit Growth
-57.14%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.60
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
19.75
PB Ratio
2.59
Price-to-FCF
-
Gross Margin
6.93%
Net Margin
-829.58%
Revenue Growth (YoY)
-58.20%
Profit Growth (YoY)
-83.39%
3-Year Revenue Growth
-44.93%
3-Year Profit Growth
-57.14%

  • When is ACRS's latest earnings report released?

    The most recent financial report for Aclaris therapeutics, inc. (ACRS) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ACRS's short-term business performance and financial health. For the latest updates on ACRS's earnings releases, visit this page regularly.

  • What is the operating profit of ACRS?

    According to the latest financial report, Aclaris therapeutics, inc. (ACRS) reported an Operating Profit of -22.33M with an Operating Margin of -1,724.63% this period, representing a growth of 77.88% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is ACRS's revenue growth?

    In the latest financial report, Aclaris therapeutics, inc. (ACRS) announced revenue of 1.3M, with a Year-Over-Year growth rate of -85.94%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does ACRS have?

    At the end of the period, Aclaris therapeutics, inc. (ACRS) held Total Cash and Cash Equivalents of 19.96M, accounting for 0.12 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does ACRS go with three margins increasing?

    In the latest report, Aclaris therapeutics, inc. (ACRS) did not achieve the “three margins increasing” benchmark, with a gross margin of -13.4%%, operating margin of -1,724.63%%, and net margin of -1,528.6%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ACRS's profit trajectory and future growth potential.

  • Is ACRS's EPS continuing to grow?

    According to the past four quarterly reports, Aclaris therapeutics, inc. (ACRS)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.16. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ACRS?

    Aclaris therapeutics, inc. (ACRS)'s Free Cash Flow (FCF) for the period is -13.16M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 47.18% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.